Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 76Nivolumab 65Ipilimumab 41Specimen Handling 34Magnetic Resonance Spectroscopy 27Cyclophosphamide 25Biopsy 20cemiplimab 16relatlimab 13fludarabine 13CTLA-4 Antigen 13binimetinib 12Radiosurgery 12Opdualag 12trametinib 11fludarabine phosphate 10avelumab 9atezolizumab 9Radiotherapy 9Immunoglobulin G 9Blood Specimen Collection 9lifileucel 8dabrafenib 8Disulfides 8encorafenib 7aldesleukin 7X-Rays 7Paclitaxel 7Standard of Care 6Interleukin-2 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paroxetine × Dermatologic × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡